Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott ADR Reporting Cited In FDA Warning Letter On Meridia, Norvir, Biaxin 

Executive Summary

Abbott expects that continued improvements to its Adverse Event Global Information System (AEGIS) will address ADR reporting problems cited in an 1FDA warning letter

You may also be interested in...



Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs

Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates

FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency

Related Content

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel